EU Medical Devices Trade with Switzerland after the Implementation of the MDR
The new EU regulation on medical devices (EU-MDR) has been enforced since May 26, 2021. However, Switzerland is not an EU Member State, which means it is considered a third country according to the new EU-MDR. This entails consequences for the trade of CE-marked medical devices between Switzerland and the EU.


Switzerland is located in Europe, but it is not an European Union (EU) Member State. It is part of the European Free Trade Association (EFTA) and belongs to the European Economic Area (EEA). EFTA has no legal obligation to follow EU product legislation and trade with Switzerland is established via multiple mutual recognition agreements.

Until now, there was a Mutual Recognition Agreement (MRA) between Switzerland and the EU for the Medical Devices Directive (MDD) and Active Implantable Devices Directive (AIMDD), which allowed medical devices (and other products like machinery and motor vehicles) to move freely between this country and the European Union Market. The EU-Switzerland MRA has previously recognized conformity assessment certificates between the EU and Switzerland based on equivalent regulations. It falls under the scope of the EU-Switzerland Institutional Framework Agreement (InstA) that has been in negotiation between the EU and Switzerland since 2014.

However, this MRA ended because the MDD and AIMDD are no longer applicable and the MRA was not updated. With the full application of the EU Medical Device Regulation (MDR – Regulation (EU) 2017/745, explained in our previous post) on May 26 this year, Switzerland became officially a “third country” to the effects of the EU-MDR. The EU has stated that in the absence of a deal regarding the implementation of the InstA, a full update of the MRA (including the medical devices chapter) cannot be considered.

The MRA has not been updated but it has not been withdrawn, so the EU Directive 98/79/EC on in vitro diagnostic medical devices (IVDD) remains mutually recognized. In 2022 (May 26th), the IVDD will be replaced by the Regulation (EU) 2017/746 (IVDR) and, in the absence of an updated MRA, in vitro medical devices will no longer be covered by the MRA, therefore happening the same as with the non-in vitro medical devices.


Until a potential agreement on the proposed modification to the MRA is reached, the trade facilitating effects of the MRA for medical devices falling under the new MDR cease to apply. As a result, this has consequences, particularly when it comes to the mutual recognition of conformity assessment results, the need for an authorized representative and the alignment of technical regulations.

The Swiss Federal Council adopted on May 19th 2021 an amendment to the Swiss Ordinance on Medical Devices (MedDO). This amendment introduces additional requirements to account for the absence of an updated MRA, establishing conditions for trade of medical devices which are covered by EU issued certificates on the Swiss market. The existing certificates (issued under the MRA) by conformity assessment bodies established in the EU are recognized and transitional timelines are granted for the designation of a representative in Switzerland for EU/EEA medical devices manufacturers.

Swiss medium and high-risk devices must be certified by conformity assessment bodies established in the EU. The existing certificates (issued under the MRA) issued by conformity assessment bodies established in Switzerland will no longer be recognized. Switzerland is disputing this EU unilateral determination and defends that transition periods should be given.

Swiss manufacturers, treated now as third country manufacturers, need to appoint a European Authorized Representative so they can export their devices to Europe. On the other hand, European manufacturers must designate a Swiss Authorized Representative to export their products to Switzerland, complying with the Medical Device Ordinance (MedDO). According to the revised MedDO, a Swiss Authorized Representative is “any natural or legal person established within Switzerland who has received a written mandate from a manufacturer located in another country to act on the manufacturer’s behalf in relation to specified tasks with regard to the latter’s obligation under this Ordinance”. A Swiss Authorized Representative is required for all medical devices, except for in-vitro medical devices (which are not concerned by the revised MedDO), all procedure packs and all systems.

Economic operators (manufacturers, importers, and authorized representatives) must register with Swissmedic in order to obtain an unique identification number (“Swiss Single Registration Number” – CHRN), within 3 months after placing a device on the market. EUDAMED (EU database on medical devices – see previous post) is not accessible to Swissmedic.

There is still a lot of uncertainty involving the medical devices trade between Switzerland and the EU and how it is going to unfold. One thing is sure, without and updated MRA, Switzerland is regarded as a third country to the effects of the EU MDR and EEA countries are third countries under the Swiss legislation on medical devices.

Critical Catalyst will continue to monitor this situation, assisting Medical Devices companies in the best way possible. If you wish to get more information on this matter or place any questions to our regulatory team, do not hesitate to contact us at


  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Available at:
  2. Commission published information notice on the status of the EU-Switzerland Mutual Recognition Agreement for Medical Devices. 26 May 2021. European Commission. Available at:


cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »
cosmetic products

European Commission Recommendation on the Definition of Nanomaterial

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. The European Commission has published a new Recommendation to clarify the definition of ‘nanomaterial’. This definition may serve different policy, legislative and research purposes when addressing materials or issues concerning products of nanotechnologies.

Read More »